{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.9404","value":"44.745"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"331"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 1 Hour Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.0407","value":"16.253"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 4 Hours Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.4420","value":"7.867"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"327"}],"units":"Participants"}],"title":"Cycle 1 Day 14: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.2770","value":"2.664"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.7411","value":"8.521"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"}],"units":"Participants"}],"title":"Cycle 2 Day 14: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.6318","value":"2.763"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"}],"units":"Participants"}],"title":"Cycle 3 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.6720","value":"8.490"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"}],"units":"Participants"}],"title":"Cycle 3 Day 14: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.1116","value":"3.284"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"}],"units":"Participants"}],"title":"Cycle 4 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.2046","value":"3.594"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"title":"Cycle 5 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.5242","value":"2.603"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"}],"units":"Participants"}],"title":"Cycle 6 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.4658","value":"2.598"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"}],"units":"Participants"}],"title":"Cycle 7 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.5549","value":"2.539"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"}],"units":"Participants"}],"title":"Cycle 8 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0867","value":"2.593"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"242"}],"units":"Participants"}],"title":"Cycle 9 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7431","value":"2.536"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"}],"units":"Participants"}],"title":"Cycle 10 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.5448","value":"2.667"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"}],"units":"Participants"}],"title":"Cycle 11 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.8949","value":"2.686"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"}],"units":"Participants"}],"title":"Cycle 12 Day 1: Pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"331"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants who were randomly assigned to receive Ixazomib 4.0 mg capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40 mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.\n\nAfter Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to end of study (up to approximately 109 months).","id":"OG000","title":"Ixazomib"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) analysis population is defined as subjects with at least one PK sample that was collected and analyzed. Overall number of participants analyzed is the number of participants available for analyses. Number analyzed indicates the number of participants available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: Post-dose at multiple timepoints up to 4 hours; Pre-dose at Cycle 1 Day 14, Cycles 2-3 Day 1 and Day 14, Cycles 4-11 Day 1 (Each cycle length = 28 days)","title":"Cmax: Maximum Plasma Concentration for Ixazomib","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter"}